Boston Scientific Corporation $BSX Shares Sold by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP decreased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 27.0% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,669 shares of the medical equipment provider’s stock after selling 1,356 shares during the quarter. Westfield Capital Management Co. LP’s holdings in Boston Scientific were worth $394,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. GDS Wealth Management raised its position in Boston Scientific by 56.2% during the 2nd quarter. GDS Wealth Management now owns 112,649 shares of the medical equipment provider’s stock worth $12,100,000 after buying an additional 40,528 shares during the last quarter. Ensign Peak Advisors Inc increased its stake in shares of Boston Scientific by 28.5% in the second quarter. Ensign Peak Advisors Inc now owns 1,251,478 shares of the medical equipment provider’s stock worth $134,421,000 after acquiring an additional 277,317 shares during the period. Saturna Capital Corp increased its stake in shares of Boston Scientific by 57.7% in the second quarter. Saturna Capital Corp now owns 41,791 shares of the medical equipment provider’s stock worth $4,489,000 after acquiring an additional 15,286 shares during the period. Empirical Finance LLC raised its holdings in shares of Boston Scientific by 0.7% during the second quarter. Empirical Finance LLC now owns 50,059 shares of the medical equipment provider’s stock worth $5,377,000 after purchasing an additional 338 shares during the last quarter. Finally, Dorsey Wright & Associates acquired a new position in Boston Scientific during the second quarter valued at $1,636,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Up 0.2%

Shares of Boston Scientific stock opened at $96.77 on Friday. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50. The firm has a market capitalization of $143.46 billion, a PE ratio of 51.75, a P/E/G ratio of 2.02 and a beta of 0.58. The firm’s 50-day moving average price is $98.97 and its 200 day moving average price is $102.38.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The business’s revenue was up 20.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insiders Place Their Bets

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the sale, the director owned 24,134 shares of the company’s stock, valued at $2,371,889.52. The trade was a 34.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,561,336.74. The trade was a 21.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 175,782 shares of company stock worth $17,742,314 in the last 90 days. 0.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Wall Street Zen raised Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 11th. Robert W. Baird raised their target price on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Royal Bank Of Canada reissued an “outperform” rating and issued a $125.00 price target on shares of Boston Scientific in a report on Monday, September 29th. Truist Financial raised their price objective on shares of Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Finally, BTIG Research reaffirmed a “buy” rating and set a $132.00 target price on shares of Boston Scientific in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $123.77.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.